Serotonin syndrome is caused by drug induced excess of intrasynaptic 5-hydroxytryptamine. The clinical manifestations are mediated by the action of 5-hydroxytryptamine on various subtypes of serotonin receptors. There is no effective drug treatment established. The history of the treatment of serotonin syndrome with 5-hydroxytryptamine blocking drugs is reviewed. A literature search was undertaken using both Medline and a manual search of the older literature. Reports of cases treated with the 5-HT2 blockers cyproheptadine and chlorpromazine were identified and analysed. There is some evidence suggesting the efficacy of chlorpromazine and cyproheptadine in the treatment of serotonin syndrome. The evidence for cyproheptadine is less substantial, perhaps because the dose of cyproheptadine necessary to ensure blockade of brain 5-HT2receptors is 20–30 mg, which is higher than that used in the cases reported to date (4–16 mg).
Ames D, Wirshing WC (1993) Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome a possible link?JAMA269: 869–870
2.
Ananth J, Luchins A (1977) A review of combined tricyclic and MAOI therapy. Comp Psychiatry18: 221–230
3.
Arnett C D, Fowler J S, MacGregor R R, Schlyer D J, Wolf A P, Lang-strom B, Halldin C (1987) Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-(11C) deprenyl. J Neurochem49: 522–527
4.
Ayd FJ (1961a) Acritique of antidepressants. Dis Nerv Syst22: 32–36
5.
Ayd F J (1961b) Toxic somatic and psychopathologic reactions to antidepressant drugs. J Neuropsychiatr2: 119–122
6.
Babiak J (1961) A case fatality of overdose of a combination of tranylcypromine (parnate) and imipramine (tofranil). Can Med Assoc J85: 377–378
7.
Baetz M, Malcolm D (1995) Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry40: 428–429
8.
Beasley C M, Masica DN, Heiligenstein J H, Wheadon DE, Zerbe R L (1993) Possible monoamine oxidase inhibitor–serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol13: 312–320
9.
Beaumont G (1973) Drug interaction with clomipramine (anafranil). J Intern Med Res1: 480–484
10.
Bedford-Russel A R, Schwartz R H, Dawling S (1992) Accidental ingestion of `ecstasy' (3, 4-methylenedioxymethamphetamine). Arch Dis Child67: 1114–1115
11.
Benazzi F (1996) Serotonin syndrome with moclobemide-fluoxetine combination. Pharmacopsychiatry29: 162–162
12.
Bodner R A, Lynch T, Lewis L, Kahn D (1995) Serotonin syndrome. Neurology45: 219–223
13.
Bogdanski DF, Weissbach H, Undenfriend S (1958) Pharmacological studies with the serotonin precursor 5-hydroxytryptophan. J Pharmacol Exp Ther122: 182–194
14.
Bowen LW (1964) Fatal hyperpyrexia with antidepressant drugs. BMJ2: 14–65
15.
Braitberg G (1994) Serotonin syndrome. Med J Aust160: 527–528
16.
Brannan S K, Talley B J, Bowden C J (1994) Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol14: 144–145
17.
Brennan D, MacManus M, Howe J, McLoughlin J (1988) Neuroleptic malignant syndrome without neuroleptics. Br J Psychiatry152: 578–579
18.
Brodribb T R, Downey M, Gilbar PJ (1994) Efficacy and adverse effects of moclobemide. Lancet343: 475–475
19.
Brown T M, Skop B P (1996) Nitroglycerine in the treatment of the serotonin syndrome. Ann Pharmacother30: 191–191
20.
Brown T M, Skop B P, Mareth T R (1996) Pathophysiology and management of the serotonin syndrome. Ann Pharmacother30: 527–533
21.
Brownlee G, Williams GW (1961) Potentiation of amphetamine and pethidine by monoamine oxidase inhibitors. Lancet1: 669–669
22.
Brubacher J R (1997) Treating the serotonin syndrome: antidote or support. J Toxicol Clin Toxicol35: 213–214
23.
Brubacher J R, Hoffman R S, Lurin M J (1996) Serotonin syndrome from venlafaxine–tranylcypromine interaction. Vet Human Toxicol38: 358–361
24.
Carlsson A, Lindqvist M (1969) Central and peripheral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines. J Pharm Pharmacol Chemother21: 460–464
25.
Carlsson A, Jonason J, Lindqvist M (1969) Demonstration of extra neuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res12: 456–460
26.
Caroff S N, Mann S C (1993) Neuroleptic malignant syndrome. Contemp Clin Neurol77: 185–202
27.
Ciocatto E, Fagiano G, Bava G L (1972) Clinical features and treatment of overdosage of monoamine oxidase inhibitors and their interaction with other psychotropic drugs. Resuscitation1: 69–72
28.
Clark WG, Lipton J M (1986) Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants: II. Neurosci Biobehav Rev10: 153–220
29.
Clement A J, Benazon D (1962) Reactions to other drugs in patients taking monoamine oxidase inhibitors. Lancet2: 197–198
30.
Cocks DP, Passmore-Rowe A H (1962) Dangers of monoamine oxidase inhibitors. BMJ2: 1545–1546
31.
Coplan D, Gorman J M (1993) Detectable levels of fluoxetine metabolites after discontinuation: an unexpected serotonin syndrome. Am J Psychiatry150: 837–837
32.
Corkeron M A (1995) Serotonin syndrome a potentially fatal complication of antidepressant therapy. Med J Aust163: 481–482
33.
Curzon G, Ettlinger G, Cole M, Walsh J (1963) The biochemical, behavioral and neurologic effects of high L-tryptophan intake in the rhesus monkey. Neurology12: 431–438
34.
Denton P H, Borrelli V M, Edwards N V (1962) Dangers of monoamine oxidase inhibitors. BMJ2: 1752–1753
35.
Espelin DE, Done A K (1968) Amphetamine poisoning. N Engl J Med278: 1361–1365
36.
Fahim J, Ismail M, Osman O H (1972) The role of 5-hydroxytryptamine and noradrenaline in the hyperthermic reaction induced by pethidine in rabbits pretreated with pargyline. Br J Pharmacol46: 414–416
37.
Felner A E, Waldmeier P C (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol28: 995–1002
38.
Fjalland B (1979) Neuroleptic influence on hyperthermia induced by 5-hydroxytryptophan and p-methoxyamphetamine in MAOI pretreated rabbits. Psychopharmacology63: 113–117
39.
Francois B, Marquet P, DesachyA, Roustan J, Lachatre G, Gastinne H (1997) Serotonin syndrome due to an overdose of moclobemide and clomipramine: a potentially life threatening association. Intens Care Med23: 122–124
40.
Gander D R (1965) Treatment of depressive illness with combined antidepressants. Lancet1: 107–109
41.
George T P, Godleski L S (1996) Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry39: 384–385
42.
Gillman P K (1995) Possible serotonin syndrome with moclobemide and pethidine. Med J Aust162: 554–554
43.
Gillman P K (1996) Successful treatment of serotonin syndrome with chlorpromazine. Med J Aust165: 345–345
44.
Gillman P K (1997a) Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust167: 109–111
45.
Gillman P K (1997b) Serotonin syndrome treated with chlorpromazine. J Clin Psychopharmacol17: 128–129
46.
Goldberg R J, Huk M (1992) Serotonin syndrome from trazadone and buspirone. Psychosomatics33: 235–236
47.
Goldberg R S, Thornton W E (1986) Combined tricyclic–MAOI therapy for refractory depression: a review with guidelines for appropriate usage. J Clin Pharmacol18: 143–147
48.
Graber M A, Hoehns T B, Perry PJ (1994) Sertraline–phenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother28: 732–735
49.
Green A R, Grahame-Smith D G (1974) The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxy-tryptamine synthesis in rats. Neuropharmacology13: 949–959
50.
Green A R, Grahame-Smith D G (1976) Effects of drugs on the processes regulating the functional activity of brain 5-hydroxy-tryptamine. Nature260: 487–491
51.
Green A R, Cross A J, Goodwin G M (1995) Review of the pharmacology and clinical pharmacology of 3, 4-methylenedioxy-methamphetamine (MDMA or `ecstasy'). Psychopharmacology119: 247–260
52.
Guze B H, Baxter L R (1986) The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol6: 119–120
53.
Halman M, Goldblum B S (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry28: 518–521
54.
Hansen T E, Dieter K, Keepers GA (1990) Interaction of fluoxetine and pentazocine. Am J Psychiatry147: 949–950
55.
Harker J, Gibson P (1995) Heat-stroke: a review of rapid cooling techniques. Intens Crit Care Nursing11: 198–202
56.
Harrer G (1961) Zur Inkompatibilitat zwischen Monoaminooxydasehemmern und Imipramin.Wien Med Wschr 111: 5–51
57.
Heisler M A, Guidry J R, Arnecke B (1996) Serotonin syndrome induced by the administration of venlafaxine and phenelzine. Ann Pharmacother30: 84–84
58.
Hernandez A F, Montero M N, Pla A, Villanueva E (1995) Fatal moclobemide overdose or death caused by serotonin syndrome?J Forensic Sci40: 128–130
59.
Hess S M, Doepfner W (1961) Behavioural effects and brain amine content in rats. Arch Int Pharmacodyn Ther134: 89–99
60.
Hess S M, Redfield B G, Underfriend S (1959) The effect of monoamine oxidase inhibitors and tryptophan on the tryptamine content of animal tissues and urine. J Pharmacol Exp Ther127: 178–178
61.
Hilton S E, Maradit H, Moller H J (1997) Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci247: 113–119
62.
Himwich WA (1962) Interaction of monoamine oxidase inhibitors with imipramine and similar drugs. Recent Adv Biol Psychiatry4: 257–257
63.
Himwich WA, Petersen JC (1961) Effect of the combined administration of imipramine and a monoamine oxidase inhibitor. Am J Psychiatry117: 928–929
64.
Hodgman M J, Martin T G, Krenzelok E P (1997) Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Human Exp Toxicol16: 14–17
65.
Horita A, Gogerty J H (1958) The pyretogenic effect of 5-hydroxy-tryptophan and its comparison with LSD. J Pharmacol Exp Ther122: 195–200
66.
Howarth E (1961) Possible synergistic effects of the new thymoleptics in connection with poisoning. J Ment Sci107: 100–103
67.
Insel T, Roy B, Cohen R, Murphy D (1982) Possible development of the serotonin syndrome in man. Am J Psychiatry139: 954–955
68.
Jahr J S, Pisto J D, Gitlin MC, O'Neill P T (1994) The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg79: 189–191
69.
Jounela A J, Mattila M J, Knoll J (1977) Interaction of selective inhibitors of monoamine oxidase with pethidine in the rabbit. Biochem Pharmacol26: 806–808
70.
Kapur S, Zipursky R B, Jones C, Wilson A A, Dasilva J D, Houle S (1997) Cyproheptadine: a potent in vivo serotonin antagonist. Am J Psychiatry154: 884–884
71.
Keltner N (1994) Serotonin syndrome: a case of fatal SSRI/MAOI interaction. Perspect Psychiatr Care30: 26–31
72.
Klee B, Kronig M H (1993) Case report of probable sertraline induced akathisia. Am J Psychiatry150: 986–987
73.
Kline S S, Mauro L S, Scala-Barnett DM, Zick D (1989) Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm8: 510–514
74.
Klysner R, LarsenJ K, Serensen P, Hyllested M, Pedersen-Dyrlund B (1995) Toxic interaction of venlafaxine and isocarboxazid. Lancet346: 1298–1299
75.
Kuisma M J (1995) Fatal serotonin syndrome with trismus. Ann Emerg Med26: 108–108
76.
Lane R, Baldwin D (1997) Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol17: 208–221
77.
Lappin R I, Auchincloss E L (1994) Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med331: 1021–1022
78.
Lejoyeux M, Fineyre F, Ades J (1992) The serotonin syndrome. Am J Psychiatry149: 1410–1411
79.
Lejoyeux M, Rouillon F, Leon E, Ades J (1995) The serotonin syndrome: review of the literature and description of an original study. Encephale22: 537–543
80.
Liebenberg R, Berk M (1996) Serotonergic syndrome after concomitant use of moclobemide and fluoxetine. Hum Psychopharmacol11: 146–147
81.
Lieberman J, Kane J M, Reife R (1985) Neuromuscular effects of monoamine oxidase inhibitors. JClin Psychopharmacol5: 221–228
82.
London D R, Milne M D (1962) Dangers of monoamine oxidase inhibitors. BMJ2: 17–52
83.
Loveless A H, Maxwell D R (1965) A comparison of the effects of imipramine trimipramine and some other drugs in rabbits treated with a monoamine oxidase inhibitor. Br J Pharmacol25: 158–170
84.
Marley E, Wozniak K M (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors. Psychol Med13: 735–749
85.
Marley E, Wozniak K M (1984a) Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res18: 173–189
86.
Marley E, Wozniak K M (1984b) Interactions of non-selective monoamine oxidase inhibitors, tranylcypromine and nialamide, with inhibitors of 5-hydroxytryptamine, dopamine and noradrenaline re-uptake. J Psychiatr Res18: 191–203
87.
Marley E, Wozniak K M (1985) Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine re-uptake, clomipramine. J Psychiatr Res19: 597–608
88.
Marsden C A, Curzon G (1979) The role of tryptamine in the behavioural effects of tranylcypromine + L-tryptophan. Neuro-pharmacology18: 159–164
89.
MartinT G (1996) Serotonin syndrome. Ann Emerg Med28: 520–526
90.
Mason B J, Blackburn K H (1997) Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother31: 175–177
91.
Mathew N T, Tietjen G E, Lucker C (1996) Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia16: 323–327
92.
Mills KC (1995) Serotonin syndrome. Am Fam Physician52: 1475–1482
93.
Mitchell R S (1955) Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med42: 417–424
94.
Moller Nielsen I (1980) Tricyclic antidepressants: general pharmacology. In Hofmeister F, Stille G (eds), Psychotropic agents part 1: antipsychotics and antidepressants. Springer-Verlag, Berlin
95.
Morch R (1962) Nogle medicamentelt fremkaldte delirose tilstande. Ugeskr Laeger124: 614–615
96.
Muly EC, McDonald W, Steffens D, Book S (1993) Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry150: 15–65
97.
Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet342: 14–19
98.
Nierenberg DW, Semprebon M (1993) The central nervous system serotonin syndrome. Clin Phamacol Ther53: 84–88
99.
Nimmo S M, Kennedy B W, Tullett W M, Blyth A S, Dougall J R (1993) Drug-induced hyperthermia. Anaesthesia48: 892–895
100.
Nymark M, Moller Neilsen I (1963) Reactions due to the combination of monoamineoxidase inhibitors with thymoleptics, pethidine or methylamphetamine. Lancet2: 524–525
101.
Oates JA, Sjoerdsma A (1960) Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology10: 1076–1078
102.
Oefele K V, Grohmann R, Ruther E (1986) Adverse drug reactions in combined tricyclic and MAOI therapy. Pharmacopsychiatry19: 243–244
103.
Ooi T K (1991) The serotonin syndrome. Anaesthesia46: 507–508
104.
Palmer H (1960) Potentiation of pethidine. BMJ2: 944–944
105.
Papp C, Benaim S (1958) Toxic effects of iproniazid in a patient with angina. BMJ2: 1070–1072
106.
Pato N T, Murphy D L, DeVane C L (1991) Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol11: 224–225
107.
Peebles-Brown A E (1985) Hyperpyrexia following psychotropic drug overdose. Anaesthesia40: 1097–1099
108.
Penn R G, Rodgers K J (1971) Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with a monoamine oxidase inhibitor. Br J Pharmacol42: 485–492
109.
Persing J S (1994) Neuroleptic malignant syndrome: an overview. S Dakota J Medicine47: 51–55
110.
Pollock R A, Watson R L (1971) Malignant hyperthermia associated with hypocalcaemia. Anesthesiology34: 188–188
111.
Power B M, Pinder M, Hackett L P, Ilett K F (1995) Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intens Care23: 499–502
112.
Razani J, White K L, White J, Simpson G, Sloane R B, Rebal R, Palmer R (1983) The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. Arch Gen Psychiatry40: 657–661
113.
Reeves R, Bullen J (1995) Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics36: 159–160
114.
Reid NC RW (1962) Pethidine and phenelzine. BMJ1: 408–408
115.
Richelson E (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther23: 94–102
116.
Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry11: 4–11
117.
Richelson E, Souder T, Acuna J, Chou T (1997) Binding studies with some new neuroleptics at human brain receptors. Biol Psychiatry41: 67S–67S
118.
Rivers N, Horner B (1970) Possible lethal interaction between Nardil and dextromethorphan. Can Med Assoc J103: 85–85
119.
Robert P, Senard J M, Fabre M, Cabot C, Cathala B (1996) Syndrome serotoninergique lors d'une intoxication aigue aux antidepresseurs. Ann Fr Anesth Reanim15: 663–665
120.
Rogers K J, Thornton JA (1969) The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br J Pharmacol36: 470–480
121.
Rosebush P, Stewart T (1989) A prospective analysis of 24 episodes of neuroleptic syndrome. Am J Psychiatry149: 717–725
122.
Rosenberg M R, Green M (1989) Neuroleptic malignant syndrome: a review of response to therapy. Ann Intern Med149: 192–731
123.
Ruiz F (1994) Fluoxetine and the serotonin syndrome. Ann Emerg Med24: 983–985
124.
Sandyk R (1986) L-Dopa induced serotonin syndrome in a Parkinsonian patient on bromocriptine. JClin Psychopharmacol6: 194–195
125.
Schuckit M, Robins E, Feighner J (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry24: 509–514
126.
Sethna E R (1974) A study of refractory cases of depressive illness and their response to combined antidepressant treatment. Br J Psychiatry124: 265–272
127.
Shee JC (1960) Dangerous potentiation of pethidine by iproniazid and its treatment. BMJ2: 507–509
128.
Sinclair J G (1973) Dextromethorphan–monoamine oxidase inhibitor interaction in rabbits. J Pharm Pharmacol25: 803–808
129.
Skop B P, Finkelstein JA, Mareth T R, Magoon M R, Brown T M (1994) The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emergency Med12: 642–644
130.
Snider S R, Hutt C S, Stein B, Fahn S (1975) Increase in brain serotonin produced by bromocriptine. Neurosci Lett1: 237–241
131.
Sovner R, Wolfe J (1988) Interaction between dextromethorphan and monoamine oxidase inhibitor therapy with isocarboxazid. N Engl J Med319: 16–71
132.
Sporer K A (1995) The serotonin syndrome implicated drugs, patho-physiology and management. Drug Safety13: 94–104
133.
Staufenberg E F, Tantum D (1989) Malignant hyperthermia syndrome in combined treatment. Br J Psychiatry154: 577–578
134.
Stern TA, Schwartz J H, Schuster J L (1992) Catastrophic illness associated with the combination of clomipramine, phenelzine, and chlorpromazine. Ann Clin Psychiatry4: 81–85
135.
Sternbach H (1991) The serotonin syndrome. Am J Psychiatry148: 705–713
136.
Tackley R M, Tregaskis B (1987) Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction. Anaesthesia42: 760–763
137.
Taylor D C (1962) Alarming reaction to pethidine in patients on phenelzine. Lancet2: 401–402
138.
Vigran I M (1964) Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride. JAMA187: 953–954
139.
WanderTJ, Nelson A, Okazaki H, Richelson E (1987) Antagonism by neuroleptics of serotonin 5-HT 1A and 5-HT 2 receptors of normal human brain in vitro. Eur J Pharmacol143: 279–282
140.
White K, Simpson G (1981) Combined MAOI–tricyclic antidepressant treatment: a reevaluation. J Clin Pharmacol1: 264–281
141.
Zornberg G L (1993) Adverse interaction between propoxyphene and phenelzine. Am J Psychiatry150: 1269–1270
142.
Zornberg G L, Bodkin JA, Cohen B M (1991) Severe adverse interaction between pethidine and selegiline. Lancet337: 246–246
